Teko e Ncha ea Kliniki bakeng sa Lihlahala Tse Matla tse Tsoetseng Pele le Hodgkin's Lymphoma

Glenmark Pharmaceuticals Limited e amohetse tumello ho tsoa ho molaoli oa lithethefatsi oa India, Molaoli Kakaretso oa Lithethefatsi oa India (DCGI), ho etsa teko ea kliniki ea Mokhahlelo oa 1 oa "molek'hule" ea eona e ncha, GRC 54276, inhibitor ea hematopoietic progenitor kinase 1 (HPK1). GRC 54276 ke e 'ngoe ea limolek'hule tse ngata tse tsoang ho moahi oa Glenmark, Innovative Medicines Group, e etelletsoeng pele ke Dr. Nikhil Amin, Ofisiri e ka Sehloohong ea Saense, ea sebetsanang le nts'etsopele ea mekhatlo e mecha ea limolek'hule bakeng sa litlhoko tsa bohlokoa tsa bongaka tse sa fihlelleheng. HPK1 ke molaoli oa bohlokoa oa T cell, B cell le dendritic cell-mediated immune reactions, e ntlafatsang ts'ireletso ea 'mele ea antitumor ka ho kenya tšebetsong le ho qala lisele tsa T. GRC 54276 e bonts'itse bokhoni ba ho bolaea lisele tsa tumor lithutong tsa preclinical e le moemeli a le mong hape hammoho le li-inhibitors tsa tlhahlobo, e leng se etsang hore e be sepheo sa pele ho immuno-oncology.

Boithuto bona bo tla lekola polokeho le mamello ea GRC 54276 joalo ka monotherapy, hape hammoho le li-inhibitors tsa tlhahlobo ho bakuli ba nang le lihlahala tse tiileng tse tsoetseng pele le Hodgkin's lymphoma. Glenmark e tla qala teko ea bongaka ea Mokhahlelo oa 1 India ka Phuptjane 2022, hape e rera ho faela IND US le Clinical Trial Applications Europe ho thakhola lenaneo la boithuto ba bongaka ba lefats'e ka bophara.

"Boiteko ba Glenmark e bile ho fana ka litharollo tse ncha tsa kalafo libakeng tsa eona tsa mantlha tsa kalafo. Re thabetse hore molek'hule ea rona ea pele e tsoang ho 'Innovative Medicines Group' e sa tsoa thehoa ka har'a Glenmark e fumane tumello ho tsoa ho molaoli oa meriana oa India ho qala teko ea bongaka ea Mokhahlelo oa 1. Sena se matlafatsa bokhoni bo ntseng bo hola ba Glenmark ba lipatlisiso tse ncha tsa bongaka 'me ke mohato o haufi oa ho fana ka litharollo tse akaretsang tsa kalafo ea mofetše," ho boletse Glenn Saldanha, Molula-setulo le Motsamaisi e Moholo, Glenmark Pharmaceuticals Limited.